Amit Saxena

Assistant Professor (Clinical) of Medicine

NYU School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Amit Saxena is an Assistant Professor (Clinical) of Medicine at NYU School of Medicine, USA. His research primarily focuses on systemic lupus erythematosus and lupus nephritis, with significant recent contributions to the understanding of treatment efficacy and safety. His notable publications include analyses of glucocorticoid usage, long-term vocational treatment effects, and the clinical implications of antibody discordance in multiethnic cohorts.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2020

Collaborators (6)

Keisha Gibson

Chief, Pediatric Nephrology

University of North Carolina at Chapel Hill

UNITED STATES

View details

Peter Izmirly

Assistant Professor of Medicine (Academic)

NYU School of Medicine

UNITED STATES

View details

Brad H Rovin

The Ohio State University Wexner Medical Center

UNITED STATES

View details

Anca D. Askanase

Columbia University Irving Medical Center

UNITED STATES

View details

Y K Onno Teng

Leiden University Medical Center

NETHERLANDS

View details

S Yasuda

Tokyo Medical and Dental University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Amit Saxena

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies

Low versus high initial oral glucocorticoid dose for lupus nephritis: a pooled analysis of randomised controlled clinical trials

Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial

A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus

Clinical and Serologic Phenotyping and Damage Indices in Patients With Systemic Lupus Erythematosus With and Without Fibromyalgia

Molnupiravir and Nirmatelvir/Ritonavir in the Treatment of Patients With Systemic Autoimmune Rheumatic Disease With SARS-CoV-2

Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial

Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis

Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay andCrithidia luciliaeassay in a multiethnic racial cohort of patients with SLE

Factors associated with long-term cardiac dysfunction in neonatal lupus

Collaborators (6)

Keisha Gibson

Peter Izmirly

Brad H Rovin

Anca D. Askanase

Y K Onno Teng

S Yasuda

Make your next move.